News Novartis' Mayzent EU approval offers SPMS patients new optio... Novartis’ Mayzent has been approved in Europe for adults with secondary progressive multiple sclerosis (SPMS) and active disease.
R&D Reuters Pharma USA 2024 – Meruno Perugini Innovation in pharma comes in many forms, but at the end of the day what the industry cares about is results.
Digital Fixing clinical trial data management It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.